相关实验视频
Updated: Jan 6, 2026

05:16
Sleeve Gastrectomy in Mice using Surgical Clips
Published on: November 14, 2020
7.2K
SGLT2抑制剂和GLP-1受体激活剂的降血压作用
Ahmed Kamal Siddiqi1, Muhammad Shahzeb Khan2,3, Anandita Kulkarni3
1Division of Cardiothoracic Imaging, Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA, USA.
Current hypertension reports
|December 1, 2025
概括
-葡萄糖共传输体-2 抑制剂 (SGLT2-i) 和类似葡萄糖-1 受体激动剂 (GLP-1RA) 显示出抗高血压的潜力. SGLT2-i提供更一致的血压降低,有利于高风险患者.
科学领域:
- 心脏病学 心脏病学
- 内分泌学 在内分泌学.
- 腎臟病學 (nephrology) 是一種醫學.
背景情况:
- 高血压是心血管疾病的主要可改变的风险因素.
- 尽管有可用的抗高血压疗法,但低于最佳的血压 (BP) 控制仍然存在.
- 糖尿病,心力衰竭 (HF) 和慢性病 (CKD) 等并发症使高血压管理复杂化.
研究的目的:
- 评估-葡萄糖携带载体-2抑制剂 (SGLT2-i) 和类似葡萄糖-1受体激动剂 (GLP-1RA) 的抗高血压疗效.
- 评估SGLT2-i和GLP-1RA在患有并发症和耐药高血压的患者中的潜力.
主要方法:
- 对评估SGLT2-i和GLP-1RA对血压影响的临床研究进行系统审查.
- 对办公室和门诊血压测量数据的分析.
- 评估安全概况和对多药物的影响.
主要成果:
- SGLT2-i 持续降低了办公室的缩血压 (SBP) 2.5-4.0 mmHg 和腹缩血压 (DBP) 1.5-2.0 mmHg.
- GLP-1RAs在特定人群中表现出适度的SBP降低 (1.8-5.1 mmHg) 与最小的DBP影响,除了特泽帕提德.
- 两种药物类别都显示出心脏脏益处,良好的安全性,并有可能减少多药性.
结论:
- 比GLP-1RA,SGLT2-i提供了比GLP-1RA更一致的降血压效果,这归因于它们的类似尿剂的作用.
- 虽然不是一线治疗,但SGLT2-i和GLP-1RA作为高风险个体的辅助疗法非常有前途.
- 需要进一步的研究来确定这些药物在综合性高血压管理中的作用.
相关概念视频
Dipeptidyl Peptidase 4 Inhibitors
540
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
540
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
496
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
496
Glucagon-like Receptor Agonists
809
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
809
Oral Hypoglycemic Agents: Biguanides and Glitazones
554
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
554
Oral Hypoglycemic Agents: Glinides
554
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
554
Antihypertensive Drugs: Angiotensin II Receptor Blockers
2.4K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.4K
